616 related articles for article (PubMed ID: 15675602)
1. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
2. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
3. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
Yan R; Bienkowski MJ; Shuck ME; Miao H; Tory MC; Pauley AM; Brashier JR; Stratman NC; Mathews WR; Buhl AE; Carter DB; Tomasselli AG; Parodi LA; Heinrikson RL; Gurney ME
Nature; 1999 Dec; 402(6761):533-7. PubMed ID: 10591213
[TBL] [Abstract][Full Text] [Related]
4. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
[TBL] [Abstract][Full Text] [Related]
5. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
Zhou S; Zhou H; Walian PJ; Jap BK
Proc Natl Acad Sci U S A; 2005 May; 102(21):7499-504. PubMed ID: 15890777
[TBL] [Abstract][Full Text] [Related]
6. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease.
Wolfe MS; Xia W; Moore CL; Leatherwood DD; Ostaszewski B; Rahmati T; Donkor IO; Selkoe DJ
Biochemistry; 1999 Apr; 38(15):4720-7. PubMed ID: 10200159
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
[TBL] [Abstract][Full Text] [Related]
8. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.
Esler WP; Kimberly WT; Ostaszewski BL; Diehl TS; Moore CL; Tsai JY; Rahmati T; Xia W; Selkoe DJ; Wolfe MS
Nat Cell Biol; 2000 Jul; 2(7):428-34. PubMed ID: 10878808
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells.
Parvathy S; Hussain I; Karran EH; Turner AJ; Hooper NM
Biochemistry; 1999 Jul; 38(30):9728-34. PubMed ID: 10423252
[TBL] [Abstract][Full Text] [Related]
10. [Pathogenesis of Alzheimer's disease: implications from amyloid research front].
Iwatsubo T
Rinsho Shinkeigaku; 2004 Nov; 44(11):768-70. PubMed ID: 15651286
[TBL] [Abstract][Full Text] [Related]
11. Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.
Li YM
Mol Interv; 2001 Oct; 1(4):198-207. PubMed ID: 14993342
[TBL] [Abstract][Full Text] [Related]
12. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of gamma-secretase inhibitors.
Josien H
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
[TBL] [Abstract][Full Text] [Related]
14. Aspartic proteases involved in Alzheimer's disease.
Schmidt B
Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
[TBL] [Abstract][Full Text] [Related]
15. A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity.
Wolfe MS; Citron M; Diehl TS; Xia W; Donkor IO; Selkoe DJ
J Med Chem; 1998 Jan; 41(1):6-9. PubMed ID: 9438016
[No Abstract] [Full Text] [Related]
16. Regulation of gamma-secretase activity in Alzheimer's disease.
Zhou S; Zhou H; Walian PJ; Jap BK
Biochemistry; 2007 Mar; 46(10):2553-63. PubMed ID: 17298085
[TBL] [Abstract][Full Text] [Related]
17. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
Citron M
Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495
[TBL] [Abstract][Full Text] [Related]
18. APPepsilon, the epsilon-secretase-derived N-terminal product of the beta-amyloid precursor protein, behaves as a type I protein and undergoes alpha-, beta-, and gamma-secretase cleavages.
Lefranc-Jullien S; Sunyach C; Checler F
J Neurochem; 2006 May; 97(3):807-17. PubMed ID: 16524370
[TBL] [Abstract][Full Text] [Related]
19. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.
Wolfe MS; De Los Angeles J; Miller DD; Xia W; Selkoe DJ
Biochemistry; 1999 Aug; 38(35):11223-30. PubMed ID: 10471271
[TBL] [Abstract][Full Text] [Related]
20. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
